1. Home
  2. BON vs AKTX Comparison

BON vs AKTX Comparison

Compare BON & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bon Natural Life Limited

BON

Bon Natural Life Limited

HOLD

Current Price

$1.70

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.28

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BON
AKTX
Founded
2006
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.6M
14.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BON
AKTX
Price
$1.70
$0.28
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
40.8K
1.9M
Earning Date
01-28-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.46
N/A
Revenue
$21,610,848.00
N/A
Revenue This Year
$223.38
N/A
Revenue Next Year
$18.82
N/A
P/E Ratio
$0.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$0.22
52 Week High
$73.75
$1.73

Technical Indicators

Market Signals
Indicator
BON
AKTX
Relative Strength Index (RSI) 47.79 37.29
Support Level $1.45 $0.27
Resistance Level $1.73 $0.31
Average True Range (ATR) 0.12 0.03
MACD 0.01 0.01
Stochastic Oscillator 67.64 66.36

Price Performance

Historical Comparison
BON
AKTX

About BON Bon Natural Life Limited

Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. Xi'an App-Chem is devoted to providing high quality and competitive prices and a stable supply of products and services for the functional food, personal care, natural medicine and other industries. It provides these products and services for third party customers, as well as for its own proprietary brands. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from Bioactive food ingredients.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: